liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhaler
Linköping University, Faculty of Health Sciences. Linköping University, Department of Clinical and Experimental Medicine, Allergy Centre . Östergötlands Läns Landsting, Centre for Medicine, Allergy Centre UHL.
Department of Respiratory Medicine Aarhus University Hospital, Denmark.
Department of Medicine Helsinki University Central Hospital, Helsinki, Finland.
Centre for Allergy Research Karolinska Institutet, Stockholm, Sweden.
2008 (English)In: Respiratory Medicine, ISSN 0954-6111, Vol. 102, no 10, 1406-1411 p.Article in journal (Refereed) Published
Abstract [en]

Background: The control of daytime and nighttime symptoms is an important measure of effectiveness of asthma therapy, especially, when administered once-daily. Objective: To evaluate the efficacy of evening and morning administrations of mometasone furoate administered via a dry powder inhaler (MF-DPI) 400 μg once-daily (QD) to show equivalence. Methods: Open-label, randomized, parallel-group study in adult patients with mild to moderate asthma with a ≥3-month history of ICS use. Patients received MF-DPI 400 μg QD either in the morning (AM) or evening (PM) for 12 weeks. The primary measure was the change in asthma symptoms from baseline to week 12. Secondary outcomes included response to treatment, adherence, inhaler device evaluation, use of rescue medication, urinary cortisol levels, and differential white blood cell count. Results: A total of 1537 patients were randomized, the efficacy population comprised 543 and 479 patients in the MF-DPI QD morning and evening groups, respectively. Mean improvements from baseline in daytime symptom scores at week 12 with morning and evening administration of MF-DPI 400 μg were -0.11 ± 0.59 and -0.12 ± 0.68, respectively (95% CI, -0.095 to 0.061) and the corresponding improvements in nighttime symptom scores were -0.08 ± 0.59 and -0.07 ± 0.50, respectively (95% CI, -0.067 to 0.068). Use of rescue medication was the same in both groups (1 puff/day). MF-DPI QD was well tolerated regardless of time of administration. Conclusions: This open-label study did not identify differences between morning and evening dosing of MF-DPI 400 μg QD. A better effect of evening dosing compared to morning dosing found in previous double-blind placebo-controlled studies could not be confirmed. © 2008 Elsevier Ltd. All rights reserved.

Place, publisher, year, edition, pages
2008. Vol. 102, no 10, 1406-1411 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-43424DOI: 10.1016/j.rmed.2008.04.024Local ID: 73824OAI: diva2:264283
Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2011-01-10

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Zetterström, Olle
By organisation
Faculty of Health SciencesAllergy Centre Allergy Centre UHL
In the same journal
Respiratory Medicine
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 29 hits
ReferencesLink to record
Permanent link

Direct link